E-LIB Suche - Ergebnisse für: Krebs-Brown, Axel

1

Bioequivalence of Related GelShieldⓇ Sustained-release Form..:

Krebs-Brown, Axel ; Brand, Kerstin M.G. ; Filho, Marco A.F. Nogueira..
Clinical Therapeutics. 46 (2024) 5 - p. 389-395 , 2024

Link: https://doi.org/10.1016/..

2

Assessment of the potential of the MET inhibitor tepotinib ..:

Yalkinoglu, Özkan ; Becker, Andreas ; Krebs-Brown, Axel...
Investigational New Drugs. 41 (2023) 4 - p. 596-605 , 2023

Link: https://doi.org/10.1007/..

3

Comment on "Levothyrox® New and Old Formulations: Are They ..:

Munafo, Alain ; Krebs-Brown, Axel ; Gaikwad, Sumedh..
Clinical Pharmacokinetics. 58 (2019) 7 - p. 969-971 , 2019

Link: https://doi.org/10.1007/..

4

Comment on: "Why Were More Than 200 Subjects Required to De..:

Krebs-Brown, Axel ; Munafo, Alain ; Gaikwad, Sumedh..
Clinical Pharmacokinetics. 59 (2019) 2 - p. 265-267 , 2019

Link: https://doi.org/10.1007/..

5

The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor R..:

Groenendaal-van de Meent, Dorien ; den Adel, Martin ; Rijnders, Sanne...
Clinical Therapeutics. 38 (2016) 4 - p. 918-928 , 2016

Link: https://doi.org/10.1016/..

6

Effect of Moderate Hepatic Impairment on the Pharmacokineti..:

Groenendaal-van de Meent, Dorien ; Adel, Martin den ; Noukens, Jan...
Clinical Drug Investigation. 36 (2016) 9 - p. 743-751 , 2016

Link: https://doi.org/10.1007/..

7

FP390MODERATE HEPATIC IMPAIRMENT HAS ONLY A MINOR IMPACT ON..:

Groenendaal−van de Meent, Dorien ; den Adel, Martin ; Noukens, Jan...
Nephrology Dialysis Transplantation. 30 (2015) suppl_3 - p. iii199-iii199 , 2015

Link: https://doi.org/10.1093/..

8

Evaluation of the CCK-4 model as a challenge paradigm in a ..:

Eser, Daniela ; Schüle, Cornelius ; Baghai, Thomas...
Psychopharmacology. 192 (2007) 4 - p. 479-487 , 2007

Link: https://doi.org/10.1007/..

9

Effect of rifampicin on the pharmacokinetics of imatinib me..:

Bolton, Ann E. ; Peng, Bin ; Hubert, Martine...
Cancer Chemotherapy and Pharmacology. 53 (2004) 2 - p. 102-106 , 2004

Link: https://doi.org/10.1007/..

10

Comparison of three microbial assay procedures for measurin..:

dos Santos, Luisa Freitas ; Defrenne, Ludwig ; Krebs-Brown, Axel
Analytica Chimica Acta. 456 (2002) 1 - p. 41-54 , 2002

Link: https://doi.org/10.1016/..

11

Assessment of the potential of the MET inhibitor tepotinib ..:

Yalkinoglu, Özkan ; Becker, Andreas ; Krebs-Brown, Axel...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447267/. , 2023

Link: http://www.ncbi.nlm.nih...

12

Comment on: "Why Were More Than 200 Subjects Required to De..:

Krebs-Brown, Axel ; Munafo, Alain ; Gaikwad, Sumedh..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007443/. , 2019

Link: http://www.ncbi.nlm.nih...

13

Effect of Moderate Hepatic Impairment on the Pharmacokineti..:

Groenendaal-van de Meent, Dorien ; Adel, Martin den ; Noukens, Jan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987405/. , 2016

Link: http://www.ncbi.nlm.nih...

14

Aliskiren-Based Therapy Lowers Blood Pressure More Effectiv..:

Capuano, V ; Schmieder, R E ; Philipp, T...
High Blood Pressure & Cardiovascular Prevention. 14 (2007) 3 - p. 145-196 , 2007

Link: https://doi.org/10.2165/..

15

P.1.c.034 Pharmacokinetics of licarbazepine in healthy volu..:

Souppart, C. ; Gardin, A. ; Greig, G....
European Neuropsychopharmacology. 16 (2006) - p. S242 , 2006

Link: https://doi.org/10.1016/..